Neogene Therapeutics Names Lee as Chief Financial Officer
15 September 2021 - - US-based preclinical stage biotechnology company Neogene Therapeutics, Inc has appointed Han Lee, Ph.D., MBA, as its chief financial officer, the company said.

Dr. Lee's experience in financial operations and corporate financing will support Neogene's global expansion as it advances its investigational therapies for a broad spectrum of cancers.

Lee has over a decade of finance experience and most recently served as chief financial officer of Arcellx, Inc. In that position, he was instrumental in helping the company transition from pre-clinical to clinical stage as he oversaw financial operations and successfully led over USD 200m in financings.

Prior to Arcellx, he was a Senior director in the Corporate Development and Ventures group at AstraZeneca, where he focused on mergers and acquisitions, corporate strategy and co-managed their equity portfolio.

Dr. Lee has led multiple-bn dollars of business development deals, financings and equity investments across more than 75 transactions. In addition, Dr. Lee was an instrumental member of two biotech start-ups with successful exits. Dr. Lee earned a Ph.D. in genetics and an MBA from Yale University.

Neogene Therapeutics is a preclinical stage biotechnology company pioneering the development of next-generation, fully individualized engineered T cells therapies for a range of cancers. Neogene's engineered T cells target mutated proteins, or neo-antigens, found in cancer cells as a consequence of cancer-associated DNA mutations.

Neo-antigens render tumor cells vulnerable to detection by T cells. Neogene's proprietary technology platform aims to identify TCR genes with specificity for neo-antigens from tumor biopsies.

Neogene's novel approach intends to deliver a tailored set of TCR genes for each individual patient, which will be engineered into patient-derived T cells directing them toward neo-antigens in tumor cells, with the goal of providing a fully individualized engineered T cell therapy for cancer.

Neogene has US headquarters in Santa Monica, CA and European headquarters in Amsterdam, NL.